Artelo's ART27.13 Shows Promise in Chemotherapy-Induced Neuropathy Model
ARTL is trading near its 52-week low of $0.961 (9.2% above the low) on light trading volume (0.2× avg).
Summary
Artelo announced positive nonclinical results for ART27.13 in a model of paclitaxel-induced peripheral neuropathy, a common chemotherapy side effect. The data, presented at ICRS 2026, showed reduced pain behaviors in animals, suggesting broader utility in cancer supportive care beyond the ongoing Phase 2 CACS trial. This adds a new potential indication for the company's lead asset, which has shown encouraging interim weight and activity trends in CACS. However, Artelo remains a micro-cap with a going concern warning and ongoing dilutive financing efforts, tempering the immediate impact. The next catalyst is completion of the CAReS trial, which includes pain endpoints to validate these preclinical findings.
At the time of this announcement, ARTL was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.96 to $85.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.